Photo credits
.jpg){kind=link}
Why Adderall Still Matters
Mixed amphetamine salts, the drug we call Adderall, are among the most effective medications in psychiatry. For adult ADHD, the effect size of amphetamines sits around 0.9 and, in some analyses, higher; that is roughly double the effect of any non-stimulant, and far above the effect sizes we accept as meaningful for antidepressants. When a correctly diagnosed patient responds, the change is often not subtle. People finish tasks they have avoided for years, stop losing their keys and their jobs, and describe, accurately, feeling like themselves for the first time.
Amphetamine is also one of the oldest drugs in the field. Charles Bradley stumbled onto its "brain medicine" effect in children in 1937, decades before ADHD had its modern name. Adderall itself is a repackaging story: the same mixed-salts formula was once marketed as the weight-loss drug Obetrol, then relaunched in 1996 as "Adderall," positioned as the thing that was not Ritalin. The pendulum of which stimulant is the reigning boogeyman has swung back and forth ever since.
None of that history changes the clinical fact underneath it: for adults who actually have ADHD, amphetamines tend to outperform methylphenidate, and roughly 80% of patients who have tried both prefer Adderall. The trade-off is equally clear. Amphetamine is a Schedule II controlled substance with real abuse and diversion potential, a meaningful cardiovascular and psychiatric side-effect profile, and a diagnosis (ADHD) that is hard to make well and easy to fake.
This guide is about prescribing it well: making the diagnosis honestly, dosing to the lowest effective dose, managing the crash and the appetite loss and the sleep, screening the heart, watching for diversion, and knowing when the right stimulant is a different one. Amphetamine is a high-value, high-responsibility drug. Writing the prescription is the easy part. The work is in the diagnosis, the dose discipline, and the monitoring around the drug.
How to Use Amphetamine - Dextroamphetamine With Confidence
Many clinicians are uneasy prescribing controlled stimulants. They don't doubt the efficacy; it's the surrounding logistics that feel fraught. Is this real ADHD or a good actor? Will this patient divert or sell? Am I going to trigger a cardiac event, a manic switch, a psychosis? Will I be the doctor who gets a call from the PDMP? Each of those has a practical answer, and prescribing amphetamine safely is achievable in any outpatient practice if you build a few habits into your system.
Hesitation 1: "Is this even ADHD?"
This is the right worry, and the one that protects patients. A patient does not have ADHD because they say they do, or because a TikTok symptom checklist matched. Attention problems are real but nonspecific, they are the final common pathway of sleep deprivation, anxiety, depression, substance use, trauma, a bad job fit, and ordinary overload.
The reassurance comes from a proper diagnostic workup, not a longer interrogation.
- Require onset of symptoms before age 12 (the DSM-5 threshold) and impairment in more than one setting (work and home, not just "I can't focus at my boring job").
- Use a standardized scale, ASRS-v1.1 for adults, Vanderbilt for children, filled out before you prescribe, so you have a baseline number to measure against.
- Actively screen the mimics: ask about sleep, alcohol/cannabis, mood, anxiety, and thyroid. Treat the sleep apnea before you blame the attention.
- When you're still unsure, a structured 1–2 month therapeutic trial with a rating scale at start and finish is itself a diagnostic tool. A clean 50% improvement in a well-screened patient is informative; a vague "I think it helped" in a poorly screened one is not.
The best defense against overprescribing is not saying no more often, it's doing the workup every time. If you can articulate why this is ADHD (childhood onset, cross-setting impairment, mimics excluded, scale-documented response), you will prescribe confidently and correctly, and you will catch the cases that aren't.
Hesitation 2: "What if I hurt their heart?"
The cardiovascular fear is larger in reputation than in reality for the healthy patient. In healthy young and middle-aged adults, large cohort data show no increased risk of serious cardiovascular events from stimulants.
Your workup is a history and vitals, not a reflexive cardiology consult:
- Ask three questions: (1) unexplained fainting or exertional syncope? (2) chest pain or palpitations that sent you to the ER? (3) any family member who died suddenly before age 35–40, or has a known inherited arrhythmia/cardiomyopathy?
- Check a baseline blood pressure and heart rate.
- A routine ECG is not required in a young, healthy patient with a clean history. Order one, and involve cardiology, only when the history, exam, or age flags something.
- Know what stops you (below): uncontrolled hypertension, recent MI or unstable angina. Cardiomyopathy, long or short QT, Brugada, Wolff-Parkinson-White and Marfan are not label contraindications, but they need a cardiology opinion before you start.
Hesitation 3: "What if they divert, misuse, or get addicted?"
Real risk, and largely manageable with structure. In non-drug-seeking patients without a substance-use history, the addiction risk from prescribed oral stimulants is roughly 1% or lower, far below alcohol. Most abuse happens via snorting or injecting for euphoria, not oral therapeutic use.
Build these habits and diversion becomes a manageable, visible problem:
- Check your state PDMP before starting and periodically after. It catches doctor-shopping and overlapping prescriptions in seconds.
- Set the refill rule out loud, on day one: one prescription per month, no early refills, no "lost/stolen" replacements without a police report or a conversation. Say it before there's a problem so it isn't personal later.
- With college students especially, do the arithmetic. Establish the intended pattern (daily? five days a week?), and note that they should return for a refill only inside the expected window. The pattern you're screening for is the semester of silence followed by a pre-exam binge-and-early-refill.
- Prefer abuse-resistant formulations when risk is elevated. Extended-release beats immediate-release, and lisdexamfetamine (Vyvanse) is almost impossible to abuse by snorting or injecting because it has to be metabolized in the body to activate. For a patient with any addiction concern who still needs an amphetamine, Vyvanse is the single best tool.
Hesitation 4: "What if I trigger mania or psychosis?"
This is the one to respect most. Amphetamines carry roughly double the psychosis risk of methylphenidate, and in pooled challenge studies a single stimulant dose produced a brief increase in positive symptoms in about 28% of patients with schizophrenia in remission and about half of those with active positive symptoms, usually lasting only hours (Curran 2004). So screen for it:
- Ask about prior mania, psychosis, and family history of bipolar I or schizophrenia.
- In a patient with bipolar disorder or a psychotic-spectrum illness, amphetamine is not your first stimulant, methylphenidate is safer, and a non-stimulant may be safer still. If you do treat, treat the mood disorder first, document stability, and monitor closely.
Amphetamine is not risky because it is a controlled stimulant. It is a controlled stimulant, so you build the structure that makes it safe. The structure is small and repeatable: an honest diagnosis with a baseline scale, a cardiac history and a blood pressure, a PDMP check, a clear refill policy, and a psychiatric-history screen for the mania/psychosis question. Do those five things and you can prescribe one of the most effective medications in psychiatry with a clear conscience, and you will be the clinician who catches the patient who shouldn't be on it.
Part 1: Indications
FDA-Approved Uses
- ADHD in children and adults (mixed amphetamine salts, IR and XR).
- Narcolepsy.
- Binge eating disorder, approved specifically for lisdexamfetamine (Vyvanse), not for the mixed amphetamine salts in Adderall. (The only FDA-approved medication for BED; NNT ≈ 4 for remission.)
The Evidence Base in ADHD
For adults, amphetamines are the more effective stimulant class. The head-to-head and meta-analytic picture (Cortese et al., Lancet Psychiatry 2018, among others):
- Amphetamines are modestly more effective than methylphenidate overall, and the advantage is most pronounced in adults; methylphenidate tends to win in children under 18.
- Effect sizes commonly cited: amphetamine-class ~0.6–1.3 depending on the analysis and population, versus methylphenidate ~0.5–0.9.
- In a large real-world survey (ADDitude, n≈4,425), 52% of adult Adderall users rated it "very effective" vs. 41% for Ritalin, and only 12% called Adderall ineffective vs. 22% for Ritalin.
- About 80% of patients who have tried both prefer Adderall.
Children respond better to methylphenidate; adults respond better to amphetamines. This is one piece of clinical lore that a modern meta-analysis confirms. Let it guide your first choice, then let the individual patient's response override it.
Off-Label and Emerging Uses (Weaker Evidence)
- Depression augmentation and bipolar depression augmentation: promising in early trials, but larger Phase III studies were negative. Not a reliable indication.
- Low-dose stimulant for age-related cognitive/energy decline in medically ill older adults (methylphenidate 5–20 mg/day is better studied here than amphetamine).
- Cancer-related fatigue and "brain fog," chronic fatigue, post-viral fatigue: used clinically, thin evidence.
Who Is a Good Candidate
- ADHD that survives the workup: childhood-onset (before age 12), cross-setting impairment, mimics excluded, ideally scale-documented.
- Adults, particularly those who have already responded to or prefer amphetamine.
- No prohibitive cardiac disease, no active psychosis or mania, no active substance use disorder.
Who Is a Poor Candidate (Proceed With Caution or Choose Another Agent)
- Active or high-risk psychotic disorder or bipolar I (mania/psychosis risk; amphetamine is worse than methylphenidate here).
- Active substance use disorder or high diversion risk (favor a non-stimulant, or Vyvanse if a stimulant is essential).
- Significant cardiovascular disease or uncontrolled hypertension.
- Prominent anxiety/obsessive-compulsive traits, which stimulants can worsen.
- The patient whose "ADHD" is actually untreated sleep deprivation, overload, or another disorder: treat the real problem.
Part 2: Workup and Candidacy
The workup for amphetamine is more clinical than laboratory. There is no routine blood level or lab panel to follow; the pre-start effort goes into the diagnosis, the heart, and the abuse screen.
The Candidacy Checklist
| Domain | What to do |
|---|---|
| Diagnosis | Confirm childhood onset (<12), cross-setting impairment; screen mimics (sleep, mood, anxiety, substances, thyroid); document a baseline ASRS/Vanderbilt. |
| Cardiac history | Ask about syncope, exertional chest pain/palpitations, and sudden death or inherited arrhythmia in relatives <35–40. |
| Vitals | Baseline blood pressure and heart rate. |
| ECG | Not routine. Order only for a positive cardiac history/exam, older patients, or known risk, then loop in cardiology. |
| Psychiatric history | Screen for personal/family bipolar I and psychosis (amphetamine can precipitate both). |
| Substance/diversion | Check the state PDMP. Ask about personal and family history of stimulant/substance misuse; chart-review the record. |
| Pregnancy | Discuss reproductive plans; pregnancy status in patients who could conceive. |
Absolute Contraindications
- Concurrent or recent (within 14 days) MAOI use: risk of hypertensive crisis.
- Known hypersensitivity to amphetamine products.
The Adderall label's only actual contraindications are those two. Uncontrolled hypertension, recent MI or unstable angina, and active psychosis are not label contraindications, but they're strong enough reasons to avoid or delay the drug that treating them as near-absolute in practice is the right call; see "Use With Caution" below for how to handle them.
Use With Caution (Relative)
- Cardiomyopathy, long or short QT syndrome, Brugada syndrome, Wolff-Parkinson-White, or Marfan syndrome. The Adderall label's only contraindications are MAOI use and hypersensitivity, but it also tells you to avoid stimulants in structural cardiac abnormality, cardiomyopathy, serious arrhythmia and coronary artery disease. Treat these as specialist-clearance items: get a cardiology opinion before starting rather than refusing outright.
The single most useful thing you can do before a first stimulant prescription is not a test, it's the differential diagnosis. If the "ADHD" evaporates once the patient sleeps 8 hours or stops drinking nightly, you've spared them a Schedule II medication they didn't need.
Part 3: How to Start and Dose
Narcolepsyall ages 6 and upFDA labelAdderall IR: usual 5 to 60 mg/day, divided. Ages 6 to 12: suggested start 5 mg daily. Ages 12 and older: start 10 mg daily.
Older adultsdose choice, all usesFDA labelMydayis: in general, start at the low end of the dosing range.In practiceTypical effective doses run low, on the order of 10 mg/day. Generally avoid above about 40 mg/day.
Kidney impairmentGFR under 30FDA labelGFR 15 to under 30: lower the dose (XR 15 mg once daily; Mydayis maximum 25 mg). End stage renal disease, GFR under 15: not recommended.In practiceImpaired kidney function can raise exposure: reduce the dose, titrate cautiously and monitor closely.
Timing and foodall uses5 rows
Stoppingall uses4 rows
Formulations
Adderall is a mixed-salts amphetamine in a 3:1 ratio of dextro- to levo-amphetamine (75% d, 25% l), combining four amphetamine salts to produce (in theory) a smoother rise and fall than pure dextroamphetamine.
Dosing Ranges and Label Limits
- Usual range: 5–40 mg/day for adult ADHD; the label says only in rare cases should the adult ADHD total exceed 40 mg/day. The 60 mg/day figure comes from the narcolepsy range rather than from ADHD dosing.
For the extended-release capsules, the Adderall XR label starts adults at 20 mg once daily in the morning and sets no adult maximum (30 mg/day is the maximum for ages 6 to 12). In the four-week adult trial of fixed doses of 20, 40 and 60 mg, all three doses beat placebo, and the label states there was not adequate evidence that doses above 20 mg/day conferred additional benefit. Both labels ask for the lowest effective dosage, individually adjusted.
If a patient is only partially responding and well below 40 mg/day with no side effects, the next step is a higher dose, still within the label limits above, rather than giving up on the drug. Titrate to effect.
Conversions (Approximate, Verify by Patient Experience)
- Amphetamine to methylphenidate: Adderall 10 mg ≈ Ritalin 20 mg (amphetamine roughly twice as potent).
- Adderall to Vyvanse: no label gives a conversion factor, and the ratio is not constant. The pediatric trial that compared the two paired Adderall XR 10 mg with Vyvanse 30 mg, 20 mg with 50 mg, and 30 mg with 70 mg (Biederman 2007; Lopez 2011). Immediate-release Adderall converts to XR at the same total daily dose (Adderall XR label), so Adderall 20 mg/day ≈ Vyvanse 50 mg and 30 mg/day ≈ 70 mg.
- Conversion tables are approximations. Absorption differs across formulations; trust the patient's reported effect and side effects over the table.
Part 4: Monitoring
Amphetamine has no therapeutic drug level and no mandatory lab schedule. Monitoring is clinical and vital-sign-based.
| What | When | Action threshold |
|---|---|---|
| Symptom rating scale (ASRS, ADHD-RS, CGI) | Baseline, then each visit during titration; periodically after | <50% improvement at adequate dose → optimize dose or switch |
| Blood pressure & heart rate | Baseline, then at each dose change and periodically | Sustained BP/HR elevation → reduce dose, reassess, treat HTN |
| Weight (and growth in children) | Baseline and periodically | Persistent/excessive loss or growth deceleration → dose reduction, drug holidays, nutritional support |
| Sleep, appetite, mood, anxiety | Every visit | Manage per side-effect section; watch for emerging mania/psychosis |
| Diversion/adherence (PDMP, pill counts, refill timing) | Before starting, then periodically | Early-refill pattern, PDMP discrepancies → address directly |
| Family/collateral input | Around 6 months and as needed | Amphetamines can inflate self-appraisal; outside perspective helps |
No routine ECG, no routine bloodwork in the stable, well-responding, low-risk patient. Escalate monitoring in the elderly, in anyone with cardiac risk, and whenever you add an interacting drug.
Part 5: Side Effects and How to Manage Them
Most amphetamine side effects are dose-dependent, front-loaded, and manageable, and many fade over the first few weeks. Manage them early, because side effects (not lack of efficacy) are the usual reason patients quit or self-discontinue.
Appetite Suppression and Weight Loss
The most common side effect, about 35% early on. Expect 8–10 lb of loss over the first months, which should then stabilize. Amphetamines suppress appetite more than methylphenidate.
Management:
- Eat before the dose and again after it wears off (breakfast pre-dose, a real dinner post-wear-off).
- Front-load calories and protein when appetite is present.
- Persistent or excessive loss calls for a dose reduction, a switch of stimulant, or drug holidays.
- In children, track growth; frank deceleration warrants dose reduction and holidays.
The "Adderall Crash"
Roughly half of patients report an evening rebound as the medication wears off: unmotivation, irritability, fatigue without restorative sleep, general misery. It is worse with immediate-release.
Management:
- Switch to a formulation that tapers off gradually (Adderall XR, or Vyvanse, which is the smoothest). For IR users, build an artificial taper: e.g., 20 mg morning, 10 mg midday, 5 mg late afternoon rather than a single big dose that falls off a cliff.
- Protect sleep, crash plus poor sleep compounds the misery.
Sleep Disturbance
About 28%, mostly when drug is still active at bedtime. (Occasionally sleep improves, as reduced rumination or the wear-off "crash" lets the patient wind down.)
Management:
- Dose earlier in the day; avoid late-afternoon IR doses.
- Use a shorter-acting form or trim the last dose.
- Do not let the stimulant paper over chronic sleep deprivation, fix the sleep.
Cardiovascular
Stimulants raise blood pressure (~1–8 mm Hg systolic) and heart rate. The absolute cardiovascular risk in healthy adults is small (roughly a 0.1 percentage-point increase in 10-year MI risk for the average user), but it scales with dose and with baseline risk. The label also carries a Peripheral Vasculopathy/Raynaud's warning: watch for digital color changes, numbness, or pain, which are usually mild and intermittent but can progress to digital ulceration; refer to rheumatology if it occurs.
Management:
- Track BP and HR at baseline and dose changes.
- For sustained elevation, reduce the dose or add/optimize antihypertensive management; an alpha-2 agonist (clonidine, guanfacine) can treat ADHD alongside the stimulant, but the guanfacine and clonidine labels do not claim it lowers the stimulant's blood-pressure effect.
- Levo-amphetamine drives more of the cardiac effect, so prefer dextro-dominant formulations (Dexedrine/Vyvanse are 100% d) in cardiac-risk patients; avoid Evekeo (1:1).
Psychiatric: Irritability, Mania, Psychosis
- Irritability (~25%) is less common than feared and often improves; more of a problem in misusers than in true ADHD. If it occurs, reduce dose or switch to methylphenidate (safer profile).
- Mania/psychosis is the serious one. Amphetamines carry ~2× the psychosis risk of methylphenidate; high doses (e.g., ~2× FDA max in narcolepsy) carry a ~12-fold psychosis risk. In pooled challenge studies a single dose produced a brief increase in positive symptoms in about 28% of patients with schizophrenia in remission and about half of those with active positive symptoms, usually lasting only hours (Curran 2004). That is a transient rise in symptom ratings, not a precipitated psychotic episode. Screen before starting; if it emerges, stop the amphetamine and reassess the diagnosis.
Dry Mouth (Xerostomia)
Common. Manage with oral rinses (Biotene, SalivaMAX). Encourage hydration and dental care.
Tics and Movement
Stimulants can exacerbate pre-existing tics; levo-amphetamine is associated with more tics than dextro. In a tic-prone patient, favor dextro-dominant formulations and monitor; alpha-2 agonists are useful adjuncts.
Other
Headache, GI upset, overstimulation/"feeling wired," and, especially in children at higher doses, personality dampening ("zombification"), which is dose-dependent and should prompt a dose reduction. High doses also impair cognition (the inverted-U curve: low doses help attention and processing speed; high doses cause rigidity, perseveration, and worse cognitive flexibility).
Part 6: Overdose, Toxicity, and Boxed Warnings
Boxed Warnings
- Abuse, misuse, and addiction. Adderall is a Schedule II controlled substance with a high potential for abuse and misuse, which can lead to a substance use disorder including addiction. Misuse and abuse can result in overdose and death, and the risk rises with higher doses and with snorting or injection. Assess abuse risk before prescribing, cover storage and disposal with the patient and family, and reassess throughout treatment.
Cardiovascular risk is not in the box. Sudden death, stroke and MI sit in Warnings and Precautions, where the label tells you to avoid stimulants in serious cardiac disease and to monitor blood pressure and pulse.
Acute Overdose
A sympathomimetic toxidrome:
- Cardiovascular: tachycardia, arrhythmia, hypertension, chest pain.
- CNS: agitation, tremor, hyperreflexia, seizures, hyperthermia.
- Psychiatric: psychosis, mania, aggression, panic.
- Severe cases: rhabdomyolysis, cardiovascular collapse.
Management is emergency care. Supportive: benzodiazepines are the mainstay for agitation, hypertension, and seizures; active cooling for hyperthermia; standard management of hypertensive emergency and arrhythmia. Do not deliberately acidify the urine to speed excretion, it risks precipitating rhabdomyolysis-related renal injury.
High-Dose and Long-Term Toxicity
- Neurotoxicity: dopaminergic terminal damage in animal models at high doses, more pronounced with amphetamines than methylphenidate.
- High-dose psychiatric consequences (from narcolepsy patients dosed near 2× max): ~12× psychosis, ~3× psychiatric hospitalization, ~4× substance abuse, ~3× suicide-attempt risk. The ceiling exists for good reasons.
Abuse Potential in Perspective
Overall addiction risk from oral, prescribed use in a non-drug-seeking patient is roughly 1% or lower. Most true abuse is via intranasal or IV routes for euphoria, and immediate-release Adderall is the most preferred formulation for getting high. Extended-release lowers abuse liability; Vyvanse's prodrug design leaves it nearly unabusable by non-oral routes.
Part 7: Drug Interactions
Absolute: MAOIs
Do not combine amphetamine with an MAOI, or start within 14 days of stopping one: risk of hypertensive crisis.
Urine and Stomach pH
Amphetamine handling is unusually pH-sensitive, and this cuts two ways:
- Absorption (gut): gastrointestinal alkalinizing agents such as antacids raise amphetamine blood levels and acidifying agents lower them. Practically, a high-fat meal delays Adderall XR absorption by ~2.5 hours.
- Excretion (kidney): this is the clinically important one. Alkalinizing the urine (e.g., sodium bicarbonate, acetazolamide) reduces amphetamine clearance and raises/prolongs levels; acidifying the urine (e.g., ascorbic acid, ammonium chloride) increases clearance and shortens the effect. Be alert to agents and conditions that shift urinary pH.
Lisdexamfetamine (Vyvanse) is converted to dextroamphetamine mainly in red blood cells, not the gut. In healthy adults a high-fat meal, yogurt and orange juice did not change its exposure (Vyvanse label), and a small study found no significant difference in exposure after Roux-en-Y gastric bypass (10 patients, 10 matched controls; Steffen 2021). The Vyvanse label gives no information on gastric pH, and urinary acidifying and alkalinizing agents change its levels as they do for other amphetamines.
CYP2D6
Amphetamine is a CYP2D6 substrate. CYP2D6 inhibitors, bupropion, duloxetine, fluoxetine, paroxetine, can raise amphetamine exposure; watch for increased effect/side effects and consider a lower dose.
Serotonergic Agents
Combining with serotonergic drugs (SSRIs/SNRIs, and especially MAOIs) carries a theoretical serotonin syndrome risk. It's usually tolerable with SSRIs, but counsel patients and stay alert.
Clinically Useful Combinations
| Combination | Effect | Management |
|---|---|---|
| + Alpha-2 agonist (clonidine, guanfacine) | Synergistic for ADHD; the label adjunctive trials show more somnolence and fatigue, and neither label reports fewer stimulant side effects | Good pairing, especially with cardiac/tic concerns |
| + Bupropion | Dopaminergic synergy for ADHD (also a 2D6 inhibitor) | Useful when ADHD + depression/tobacco; watch for raised amphetamine levels |
| + Antipsychotic | Paradoxical (agonist vs. blocker); antipsychotic blunts cognitive benefit, stimulant may worsen psychosis | Avoid starting the combination; if inherited, taper carefully after confirming rationale; methylphenidate safer than amphetamine here |
| + Benzodiazepine | No dangerous pharmacokinetic interaction | Monitor for CNS effects |
| + Alcohol | Amphetamine can mask intoxication, lowering perceived tolerance | Counsel: start with a single drink and observe |
Part 8: Special Populations
Pregnancy
Human safety data are limited and imperfect. Amphetamine crosses the placenta; signals include modestly increased risk of low birth weight, preterm birth, and possible cardiac malformations, alongside neonatal effects (agitation, poor feeding). This is a shared decision: many patients with mild-to-moderate ADHD can pause the stimulant during pregnancy, while some with severe functional impairment reasonably continue after weighing risks with the patient and obstetrics. Use the lowest effective dose and coordinate care.
Lactation
Amphetamine is excreted into breast milk and reaches measurable infant levels; most guidance is cautious. If a patient chooses to breastfeed while taking it, use the lowest effective dose, prefer once-daily/shorter exposure, and monitor the infant for irritability, poor feeding, poor weight gain, and sleep disruption, in coordination with pediatrics.
Elderly
- Lower doses suffice and are safer. Typical effective doses run low, on the order of ~10 mg/day of amphetamine/dextroamphetamine.
- Older adults are more susceptible to cardiovascular and neurotoxic effects; brain amphetamine exposure runs higher at a given dose.
- Check a baseline ECG if any cardiac history, monitor BP closely, and generally avoid dosing above ~40 mg/day. For pure cognitive/energy augmentation in the medically ill elderly, low-dose methylphenidate is the better-studied stimulant.
Renal and Hepatic Impairment
Specific dosing guidance is limited. Amphetamine is partly renally excreted (and pH-dependent), so impaired renal function can raise exposure, reduce the dose and titrate cautiously with closer monitoring. In hepatic impairment, expect reduced metabolism and dose conservatively.
Children and Adolescents
- Methylphenidate is generally first-line under 18 (better tolerated, better response rates in children, less insomnia and appetite suppression). Reserve amphetamine for methylphenidate non-response or a clear prior amphetamine response.
- Start weight-based (~0.5 mg/kg/day amphetamine), titrate to effect, and track growth and weight.
- Behavioral scaffolding is not optional: parent training, school coordination, and structure amplify medication and sometimes replace the need for higher doses. Address classroom learning issues before escalating medication.
- Misuse and diversion risk rises around age 14–15, when adolescents can control their own dosing. Count pills, watch refills, and educate against sharing or selling (a substantial minority of students with prescriptions are asked to divert).
Part 9: Discontinuation
Stopping amphetamine is not medically dangerous. There is no life-threatening withdrawal syndrome as there is with alcohol, benzodiazepines, or opioids.
What actually happens on stopping:
- After sustained daily use, patients may have days to a couple of weeks of fatigue, low motivation, and irritability, a dysphoric rebound, not physical danger and not addiction-like craving.
- The ADHD symptoms return, which can meaningfully impair work, family life, and driving.
How to stop:
- For low-to-moderate doses, an abrupt stop is medically fine, though many patients appreciate a brief taper to soften the rebound.
- For higher doses (above 40 mg/day), taper by roughly 10 mg per month with monitoring.
- Supply-chain interruptions and formulation switches are common and safe medically, but leave patients symptomatic, plan bridges so patients aren't abruptly untreated.
Distinguish physical withdrawal (minimal) from loss of an effective treatment (significant). The risk of stopping isn't a withdrawal crisis, it's a patient who slides quietly back into the impairment that brought them in. Reassess whether ADHD treatment is still needed rather than assuming lifelong therapy; many children, in fact, take stimulants only 2–3 years.
Part 10: Adderall vs. the Alternatives
vs. Methylphenidate. The central choice. Amphetamines are modestly more effective, especially in adults; methylphenidate is better tolerated, safer across comorbidities, and less likely to trigger mania or psychosis, and is preferred in children. The default: methylphenidate first-line for safety, amphetamine when the patient has responded to or prefers it, or when methylphenidate underdelivers.
Adderall vs. Vyvanse (lisdexamfetamine). Same drug family, different delivery. Vyvanse gives the smoothest levels (fewer peaks/troughs, less crash), the lowest abuse potential (prodrug), exposure that food does not change, and a longer duration, at meaningfully higher cost. About half of patients prefer it; the other half would rather go back to Adderall. Adderall XR is cheaper and effective but often needs a second daily dose despite the "XR" label.
Adderall vs. Mydayis. Mydayis extends coverage to ~16 hours for patients whose day runs long; otherwise incremental.
vs. Dexedrine / Zenzedi (100% dextro). Purer dextroamphetamine, useful when you want to minimize levo-driven cardiac effects and tics, or need fine dose granularity (Zenzedi's 7 strengths).
Avoid Evekeo (1:1 d:l) in most patients: more levo means more cardiac effect and more tics, with no efficacy advantage.
vs. Non-stimulants (atomoxetine, bupropion, alpha-2 agonists). Effect size ~0.45, roughly half that of stimulants. Reserve for stimulant failure/intolerance, substance-use concerns, or specific comorbidities (bupropion for depression/tobacco; guanfacine/clonidine for hypertension or tics).
Why is amphetamine sometimes over- and sometimes under-used? Diagnostic imprecision drives overprescribing at the front door; fear of controlled substances leaves true responders undertreated. Both errors are solved by the same discipline: an honest diagnosis and dosing to effect at the lowest effective dose.
Mechanism
Amphetamine boosts dopamine and norepinephrine in the synapse by two mechanisms, which is what distinguishes it from methylphenidate:
- Blocks the dopamine and norepinephrine reuptake transporters (like methylphenidate), keeping more neurotransmitter in the synapse; and
- Reverses the transporters and displaces stored dopamine and norepinephrine out of the presynaptic terminal, actively releasing more into the synapse.
That second, releasing action explains amphetamine's slightly greater efficacy, and its greater rewarding/abuse potential, relative to methylphenidate, which only blocks reuptake.
Isomers matter. Dextroamphetamine is 2–4× more potent than levoamphetamine, with higher abuse potential, more appetite suppression, and shorter duration; levoamphetamine is longer-lasting but carries more cardiac side effects and more tics. Adderall's 3:1 d:l blend is the compromise; Dexedrine and Vyvanse are pure dextro.
Lisdexamfetamine (Vyvanse) is dextroamphetamine chemically tethered to L-lysine, an inactive prodrug that must be cleaved (in red blood cells) to release active drug at a rate-limited pace. That yields a smooth, plateau-like level, exposure that food does not change, and abuse resistance.
Clinically, the effect follows an inverted-U: low-to-moderate doses sharpen attention and processing, while excessive doses cause rigidity, perseveration, worse cognitive flexibility, and toxicity. Past the effective dose, more is not better.
The Bedside Cheat Sheet
Diagnosis first
- Childhood onset (<12), cross-setting impairment, mimics excluded, baseline ASRS/Vanderbilt
- Check the PDMP. Screen personal/family bipolar, psychosis, and substance misuse
Starting
- Adults: Adderall IR 5 mg once-twice daily or XR 10 mg QAM (XR label start for adults: 20 mg); kids ~0.5 mg/kg/day
- Titrate weekly; 1–2 month trial, ≥50% scale improvement = response
- Find the dose on IR, then convert to XR/Vyvanse for smooth once-daily coverage
Dose limits
- Label (IR): 40 mg/day in ADHD, exceeded only in rare cases; 60 mg/day (narcolepsy). XR: 30 mg/day to age 12; adult trials tested up to 60 mg
- Titrate to effect, at the lowest effective dose
Cardiac
- History + baseline BP/HR. ECG only if history/exam/age flags it
- Hard stop (label): no MAOIs (or within 14 days). Not label contraindications, but treated as near-absolute: uncontrolled HTN, recent MI. Cardiomyopathy, long/short QT, Brugada, WPW, Marfan: cardiology clearance first, not an automatic refusal
Side effects
- Appetite/weight: eat before dose; track growth in kids
- Crash (~50%): XR/Vyvanse taper
- Sleep: dose earlier, shorter-acting, trim last dose
- Dry mouth: Biotene/SalivaMAX; hydration and dental care
- Mania/psychosis: screen first; stop and reassess if it emerges (amphetamine ~2× methylphenidate's risk)
Interactions & pearls
- No MAOIs. CYP2D6 inhibitors (bupropion, fluoxetine, paroxetine, duloxetine) raise levels
- Urine pH: alkalinizers raise levels; acidifiers lower them. Vyvanse exposure is unchanged by food, but urinary pH agents still matter
- Alpha-2 agonists pair well for efficacy (they add somnolence and fatigue)
Choosing
- Adults to amphetamine; kids to methylphenidate
- Abuse risk: Vyvanse (nearly unabusable). Cardiac/tic risk: dextro-dominant, avoid Evekeo
Stopping
- Not medically dangerous; expect days-weeks of fatigue/dysphoria and return of ADHD symptoms
- Taper ~10 mg/month if high-dose
Amphetamine is one of the most effective drugs in psychiatry and one of the easiest to prescribe carelessly. For a correctly diagnosed adult with ADHD, mixed amphetamine salts can restore a functional life in a way few medications can. The risks are just as concrete: diversion, cardiac and psychiatric events, the temptation to overdose a partial responder. They are also systematically manageable, and caution by itself is not what manages them. A system does: a disciplined diagnosis, a documented baseline, an honest cardiac and abuse screen, dose discipline, and a partnership with the patient around monitoring and refills. Do those things and amphetamine is what it should be: not a drug to fear, but a high-value tool handled with the respect a Schedule II stimulant earns.